<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171414</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P17 3.2</org_study_id>
    <secondary_id>2019-000660-25</secondary_id>
    <nct_id>NCT04171414</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Moderate to Severe Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With&#xD;
      Active Rheumatoid Arthritis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CT-P17, containing the active ingredient adalimumab, is a recombinant humanized monoclonal&#xD;
      antibody that is being developed as a similar biological medicinal product to Humira. The&#xD;
      purpose of this study is to evaluate usability of subcutaneous auto-injector of CT-P17 in&#xD;
      patients with moderate to severe rheumatoid arthritis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Actual">April 24, 2020</completion_date>
  <primary_completion_date type="Actual">November 4, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>The usability of CT-P17 Auto Injector is measured by participant using PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules. The PRE-SIAQ module is a 7-item questionnaire and the POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions before after injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scal. (each item graded on a 5-point scale). [Scores were transformed to Rate between 0 (worst) to 10 (best)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24</measure>
    <time_frame>Week 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer's Rating of Successful Self-injection Using Self-injection Assessment Checklist at Weeks 0, 2, 4, and 24</measure>
    <time_frame>Week 0,2,4,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean for Actual Values and Change From Baseline in DAS28 (CRP and ESR)</measure>
    <time_frame>Week 8,16,24</time_frame>
    <description>DAS28 (CRP) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(CRP+1) + 0.014 X GH on VAS + 0.96. DAS28 (CRP) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity.&#xD;
DAS28 (ESR) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(ESR) + 0.014 X GH on VAS. DAS28 (ESR) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity.&#xD;
Abbreviation: CRP, C-reactive protein; DAS28, Disease Activity Score using 28 joint counts; ESR, Erythrocyte sedimentation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>&quot;CT-P17 SC AI (adalimumab)&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-P17 Subcutaneous(SC) Autoinjector(AI) (adalimumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P17 SC AI (adalimumab)</intervention_name>
    <description>Subcutaneous Injection of Adalimumab 40mg once every two weeks</description>
    <arm_group_label>&quot;CT-P17 SC AI (adalimumab)&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient aged 18 to 70 years, inclusive.&#xD;
&#xD;
          -  Patient must be able and willing to self-administer subcutaneous (SC) injections via&#xD;
             auto injector (AI).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has previously received investigational or licensed product; biologic or&#xD;
             targeted synthetic disease-modifying antirheumatic drugs for the treatment of&#xD;
             rheumatoid arthritis and/or a tumor necrosis factor (TNF) Î± inhibitor for any&#xD;
             purposes.&#xD;
&#xD;
          -  Patient who has allergies to any of the excipients of study drug or any other murine&#xD;
             and human proteins, or patient with a hypersensitivity to immunoglobulin products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MinJi Ma</last_name>
    <role>Study Chair</role>
    <affiliation>Celltrion, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nasz Lekarz Osrodek Badan Klinicznych</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <results_first_submitted>August 16, 2021</results_first_submitted>
  <results_first_submitted_qc>October 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2021</results_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT04171414/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT04171414/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>&quot;CT-P17 SC AI (Adalimumab)&quot;</title>
          <description>The CT-P17 (40mg/0.4mL) was administered every other week (EOW) by subcutaneous (SC) injection via autoinjector (AI) from Week 0 to Week 24 in combination with methotrexate (MTX) and folic acid.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>&quot;CT-P17 SC AI (Adalimumab)&quot;</title>
          <description>The CT-P17 (40mg/0.4mL) was administered every other week (EOW) by subcutaneous (SC) injection via autoinjector (AI) from Week 0 to Week 24 in combination with methotrexate (MTX) and folic acid.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" lower_limit="19" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4</title>
        <description>The usability of CT-P17 Auto Injector is measured by participant using PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules. The PRE-SIAQ module is a 7-item questionnaire and the POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions before after injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scal. (each item graded on a 5-point scale). [Scores were transformed to Rate between 0 (worst) to 10 (best)]</description>
        <time_frame>Week 4</time_frame>
        <population>Usability and Intent-to-Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;CT-P17 SC AI (Adalimumab)&quot;</title>
            <description>The CT-P17 (40mg/0.4mL) was administered every other week (EOW) by subcutaneous (SC) injection via autoinjector (AI) from Week 0 to Week 24 in combination with methotrexate (MTX) and folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4</title>
          <description>The usability of CT-P17 Auto Injector is measured by participant using PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules. The PRE-SIAQ module is a 7-item questionnaire and the POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions before after injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scal. (each item graded on a 5-point scale). [Scores were transformed to Rate between 0 (worst) to 10 (best)]</description>
          <population>Usability and Intent-to-Treat (ITT) population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feelings about self-injections (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="2.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feelings about self-injections (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.16" spread="2.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-confidence (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" spread="1.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-confidence (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.07" spread="1.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-image (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.39" spread="2.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain and skin reactions during or after the injection (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.59" spread="0.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of use of the self-injection device (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.70" spread="1.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with self-injection (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" spread="1.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with self-injection (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.23" spread="1.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24</title>
        <time_frame>Week 0</time_frame>
        <population>Usability and Intent-to-Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;CT-P17 SC AI (Adalimumab)&quot;</title>
            <description>The CT-P17 (40mg/0.4mL) was administered every other week (EOW) by subcutaneous (SC) injection via autoinjector (AI) from Week 0 to Week 24 in combination with methotrexate (MTX) and folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24</title>
          <population>Usability and Intent-to-Treat (ITT) population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feelings about self-injections (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.39" spread="2.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feelings about self-injections (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.04" spread="2.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-confidence (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="2.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-confidence (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="2.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-image (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.35" spread="2.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain and skin reactions during or after the injection (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.48" spread="1.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of use of the self-injection device (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.40" spread="1.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with self-injection (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="1.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with self-injection (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="1.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observer's Rating of Successful Self-injection Using Self-injection Assessment Checklist at Weeks 0, 2, 4, and 24</title>
        <time_frame>Week 0,2,4,24</time_frame>
        <population>Usability and Intent-to-Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;CT-P17 SC AI (Adalimumab)&quot;</title>
            <description>The CT-P17 (40mg/0.4mL) was administered every other week (EOW) by subcutaneous (SC) injection via autoinjector (AI) from Week 0 to Week 24 in combination with methotrexate (MTX) and folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Observer's Rating of Successful Self-injection Using Self-injection Assessment Checklist at Weeks 0, 2, 4, and 24</title>
          <population>Usability and Intent-to-Treat (ITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0, Successful Self-Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0, Overall Successful Self-Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Successful Self-Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Overall Successful Self-Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Successful Self-Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Overall Successful Self-Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Successful Self-Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Overall Successful Self-Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean for Actual Values and Change From Baseline in DAS28 (CRP and ESR)</title>
        <description>DAS28 (CRP) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(CRP+1) + 0.014 X GH on VAS + 0.96. DAS28 (CRP) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity.&#xD;
DAS28 (ESR) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(ESR) + 0.014 X GH on VAS. DAS28 (ESR) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity.&#xD;
Abbreviation: CRP, C-reactive protein; DAS28, Disease Activity Score using 28 joint counts; ESR, Erythrocyte sedimentation rate</description>
        <time_frame>Week 8,16,24</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;CT-P17 SC AI (Adalimumab)&quot;</title>
            <description>The CT-P17 (40mg/0.4mL) was administered every other week (EOW) by subcutaneous (SC) injection via autoinjector (AI) from Week 0 to Week 24 in combination with methotrexate (MTX) and folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean for Actual Values and Change From Baseline in DAS28 (CRP and ESR)</title>
          <description>DAS28 (CRP) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(CRP+1) + 0.014 X GH on VAS + 0.96. DAS28 (CRP) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity.&#xD;
DAS28 (ESR) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(ESR) + 0.014 X GH on VAS. DAS28 (ESR) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity.&#xD;
Abbreviation: CRP, C-reactive protein; DAS28, Disease Activity Score using 28 joint counts; ESR, Erythrocyte sedimentation rate</description>
          <population>ITT population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.248" spread="0.8415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP, Week 8, Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.560" spread="1.1223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP, Week 16, Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.795" spread="1.2381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP, Week 24, Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.111" spread="1.1109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.190" spread="0.7360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR, Week 8, Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.287" spread="1.3525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR, Week 16, Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.495" spread="1.4695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR, Week 24, Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.799" spread="1.4287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24</title>
        <time_frame>Week 2</time_frame>
        <population>Usability and Intent-to-Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;CT-P17 SC AI (Adalimumab)&quot;</title>
            <description>The CT-P17 (40mg/0.4mL) was administered every other week (EOW) by subcutaneous (SC) injection via autoinjector (AI) from Week 0 to Week 24 in combination with methotrexate (MTX) and folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24</title>
          <population>Usability and Intent-to-Treat (ITT) population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feelings about self-injections (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.93" spread="2.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feelings about self-injections (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.08" spread="2.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-confidence (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" spread="2.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-confidence (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="1.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-image (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" spread="2.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain and skin reactions during or after the injection (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.64" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of use of the self-injection device (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.34" spread="1.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with self-injection (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" spread="2.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with self-injection (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.16" spread="1.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24</title>
        <time_frame>Week 24</time_frame>
        <population>Usability and Intent-to-Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;CT-P17 SC AI (Adalimumab)&quot;</title>
            <description>The CT-P17 (40mg/0.4mL) was administered every other week (EOW) by subcutaneous (SC) injection via autoinjector (AI) from Week 0 to Week 24 in combination with methotrexate (MTX) and folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24</title>
          <population>Usability and Intent-to-Treat (ITT) population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feelings about self-injections (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.88" spread="2.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feelings about self-injections (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" spread="1.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-confidence (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.21" spread="1.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-confidence (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.44" spread="1.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-image (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.04" spread="1.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain and skin reactions during or after the injection (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.60" spread="0.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of use of the self-injection device (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" spread="1.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with self-injection (PRE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.83" spread="1.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with self-injection (POST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.95" spread="1.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed from the date the patient signed the ICF until EOS/ED visit. (up to week 28, including 4 weeks of follow-up period)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>&quot;CT-P17 SC AI (Adalimumab)&quot;</title>
          <description>The CT-P17 (40mg/0.4mL) was administered every other week (EOW) by subcutaneous (SC) injection via autoinjector (AI) from Week 0 to Week 24 in combination with methotrexate (MTX) and folic acid.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="62" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="62" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="62" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="62" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="62" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="62" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="62" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="62" subjects_affected="13" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="62" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="62" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="62" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="62" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>JiWoong Lim</name_or_title>
      <organization>Celltrion Inc.</organization>
      <phone>032-850-5806</phone>
      <email>jiwoong.lim@celltrion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

